Back to top
more

Capricor Therapeutics (CAPR)

(Delayed Data from NSDQ)

$28.38 USD

28.38
3,094,982

+0.43 (1.54%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $28.69 +0.31 (1.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis

by Debanjana Dey

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for February 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 3rd

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for January 28th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 28th

Zacks Equity Research

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CHF Solutions System to be Used in JAHVH Study After Final Nod

by Zacks Equity Research

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.

Zacks Equity Research

Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.

Zacks Equity Research

Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System

by Zacks Equity Research

Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.

Zacks Equity Research

Align Gains on Innovation Despite Poor Case Shipment in China

by Zacks Equity Research

Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.

Zacks Equity Research

Natera (NTRA) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Natera (NTRA) is likely to maintain the current high on a number of favorable factors.